Recurrent Sigmoid Diverticulitis After Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for Bladder Cancer
Tóm tắt
Bacillus Calmette-Guérin (BCG), a live attenuated strain of Mycobacterium bovis, is a popular adjunctive therapy for superficial bladder cancer as it triggers local immune response. Localized cystitis is a common complication, but systemic infections or sepsis is rare. Diverticulitis has never been reported as a complication of intravesical BCG use. We report two episodes of sigmoid diverticulitis in a patient with urinary bladder papillary urothelial carcinoma after each intravesical BCG treatment, which subsided after the BCG treatment was discontinued. This case report raises awareness of acute diverticulitis as a potential side effect of intravesical BCG therapy for superficial bladder cancer. The use of antibiotics in concurrence with intravesical BCG therapy should be used with caution as evidence is not sufficient to evaluate the effect of antibiotics on BCG. Therefore, a change in therapy is warranted if recurrence of diverticulitis occurs and requires antibiotic therapy.
Tài liệu tham khảo
Alessandrino F, Ghaith O, Williams K, Sonpavde GP, Silverman SG, Shinagare AB. Advanced urothelial cancer: a radiology update. Abdom Radiol (NY). 2019;44(12):3858–73.
Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis. 2000;31(Suppl 3):91.
Chang SS. Re: Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer. J Urol. 2019;202(3):457–8.
Samannodi M, Villavicencio A, Zhao A, Chavez V, Ericsson CD. Case report: Mycobacterium bovis orchitis post intravesical Bacillus Calmette Guerin. IDCases. 2018;14:e00465.
Ebbell B. Theœ papyrus Ebers. Levin & Munksgaard: Copenhagen; 1937.
Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2003;79(938):672–80.
Felgner S, Kocijancic D, Frahm M, Weiss S. Bacteria in Cancer therapy: renaissance of an old concept. Int J Microbiol. 2016;2016:8451728.
Lamm DL, Van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596–600.
Robinson ARL, Radhakrishnan R, Horvath R, Pandey S. A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guérin therapy for superficial urinary bladder cancer. Intern Med J. 2017;47(7):820–3.
Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Tejido A, San Juan R, et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014;93(17):236–54.
Jiang SJ, Ye LY, Meng FH. Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: a meta-analysis and systematic review. Oncol Lett. 2016;11(4):2751–6.